ASCO 2019 | IMpassion130: Implications

Peter Schmid

Peter Schmid, MD, PhD, FRCP, of the Barts Cancer Institute, London, UK, discusses the implications of the results gleaned form the IMpassion130 trial (NCT02425891). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video